Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), adalimumab (ADA) in patients with psoriatic arthritis...

Full description

Bibliographic Details
Main Authors: E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-06-01
Series:Современная ревматология
Subjects:
psoriatic arthritis
tofacitinib
adalimumab
biologic disease-modifying antirheumatic drug
targeted synthetic disease-modifying antirheumatic drug
remission
minimal disease activity
Online Access:https://mrj.ima-press.net/mrj/article/view/1145

Internet

https://mrj.ima-press.net/mrj/article/view/1145

Similar Items